Follow the Pundits
Tag: HedgeFunds
🏒 Glenview Capital & Larry Robbins: The $5.5B “Hockey Jersey” Hedge Fund Slashing Wall Street 🏥⚡
Larry Robbins has built Glenview Capital around fundamental research, concentrated conviction and an unusual willingness to act like an owner. We examine its ~$5.5B Q2 2026 portfolio, CVS activism, healthcare bets, extraordinary early track record—and why hockey may explain more about Robbins than you'd expect. 🏒
⚾ Steve Cohen's Point72: Inside the $58.5B Alpha Factory, "Hogwarts" for Analysts, and the $3.4B Payday 💰📈
Steve Cohen didn't simply build another hedge fund.
He engineered an institutional investment machine.
Discover how Point72's Academy, 200+ autonomous investment pods, Cubist quantitative platform, and disciplined organizational design transformed it into one of Wall Street's most formidable alpha factories.
🏛️ Mario Gabelli & GAMCO Investors: Inside the 14.1% Compounding Machine, PMV Investing, and the $11.2 Billion Value Vault
Mario Gabelli transformed value investing by asking a different question: What would an informed buyer pay for the entire business? We explore the PMV framework, the Catalyst™ strategy, GAMCO's $36.6 billion asset base, 1,019-stock portfolio, and nearly five decades of compounding.
🍾 Third Point LLC: The Velvet Crowbar of Event-Driven Alpha
Daniel Loeb doesn't merely invest in change—he often creates it. From activist campaigns and event-driven investing to new positions in gold and crypto, here's a deep dive into Third Point's latest portfolio moves and what they may signal for investors.
🤫 ValueAct Capital Portfolio 2026: The Quiet Activist Fund Rewiring Corporate America
ValueAct Capital doesn’t fight corporate wars in public — it quietly rewires companies from inside the boardroom. Discover the fund’s $5.9B 2026 portfolio, biggest stock bets, stealth activist strategy, and why Wall Street fears the calmest investors the most.
Ackman IPO: Genius Play or Structural Trap? 🎩📉
Bill Ackman is opening the gates to his investing empire—but is this IPO a golden ticket or a cleverly packaged trade-off? From NAV discounts to DIY replication, here’s the real audit behind the hype.
🏰 The $387 Billion Macro-Machine: Inside Fisher Investments (2026 Edition)
Fisher Investments doesn’t start with stocks—it starts with the world. With $387B under management, this macro-first powerhouse takes a very different approach to investing. Here’s what’s really going on under the hood.
Biotech Hedge Fund Extraordinaire Baker Bros. Advisors LP Adds To Its Stake in Madrigal Pharmaceuticals (MDGL): Should You Buy?
When the Baker Bros. — biotech’s most famous hedge fund — start scooping up more shares of Madrigal Pharma (MDGL), you know something’s cooking. With Rezdiffra sales booming, losses shrinking, and Wall Street titans circling, the tune of this Madrigal might be worth humming 🎶.
Paul Tudor Jones Loves IWM. Should You?
Paul Tudor Jones is going heavy on small caps—and maybe prepping for AI-induced doom. With 1,350+ positions and an options playbook that could fill a library, what’s his real bet? And more importantly: should you follow? Read on, but don’t YOLO.
🎶 Paul Singer of Elliott Investment Management L.P. Never Sings Out of Tune
With a $72.7B AUM symphony, Paul Singer’s Elliott Investment Management conducts activist investing like a maestro — dissonance included. Here's why their sharp portfolio and sharper strategy deserve your attention (and maybe your applause). 🎻📈